All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
9 warning events since 2017; the latest 2026-01-15.
From the record
Serina Therapeutics, Inc.'s filings since 2017 show 9 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 7 times, the latest 2026-01-15); an auditor change (8-K item 4.01, 2 times, the latest 2024-05-03) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-25.7% a year over 9 filed years; profitable in 1 of 8.
From the record
Serina Therapeutics, Inc.'s 9 filed years say what it did: revenue went from $1 million in fiscal 2017 to $130 thousand in fiscal 2025, down 25.7% a year; it rose in 3 of 8 years; the deepest fall was 98% from fiscal 2023 to fiscal 2024; net income was positive in 1 of 8 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 9.9/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Serina Therapeutics, Inc.'s shareholder treatment is put at 9.9 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 1% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
Leverage 101%: owes 101¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Serina Therapeutics, Inc.'s shareholders' equity was below zero, so the profit on it is not read. Leverage: it owed about 101 cents per dollar of assets, and net share issuance: its share count grew 38.5% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 32% of 315 in its family; net margin -14755.4%.
From the record
Serina Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $130 thousand in fiscal 2025 ranks in the bottom 9% by size; a net margin of -14755.4% ranks in the bottom 9%; revenue growth of 56.4% a year over the last 3 filed years ranks in the top 22% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 8% of 315 in its family for leadership; chief executive since 2024.
From the record
Serina Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Ledger, Steven A (Chief Executive Officer, as filed), filing under that title since the record of its people begins (2024-04-03), so the years before are not on the record and this part is not read; the 11 officers and directors filing in the last fifteen months have been on the record a median of 2.3 years (bottom 10%); 16 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (bottom 6%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 45% of 273 in its family for room to expand.
From the record
Serina Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $3 million against no long-term debt tagged leaves 44% of its assets as net cash, top 35% of its family; cash from operations less capital spending is -13856.9% of revenue (bottom 7%); research spending of 10119.2% of revenue (top 6%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 21% of 306 in its family for growth drivers.
From the record
Serina Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 56.4% a year over the last three filed years against -25.7% over all 9, speeding up (top 6% of its family); the newest year grew 132.3% (top 13%); research spending grew 134.1% a year (top 1%); capital spending grew -32.8% a year (bottom 35%) (its annual reports). Serina Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 31% of 233 in its family for expectations against reality.
From the record
Serina Therapeutics, Inc.'s newest year against its own record: revenue of $130 thousand in fiscal 2025 came in 80.9% above the $72 thousand its prior three years' pace pointed to (top 17% of its family); net income of $19 million against a prior three-year average of $3 million (bottom 3%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 8%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made